TY - JOUR T1 - Research barriers in children and young people with life-limiting conditions: a survey JF - BMJ Supportive & Palliative Care JO - BMJ Support Palliat Care SP - e715 LP - e721 DO - 10.1136/bmjspcare-2018-001521 VL - 12 IS - e5 AU - Jordana Natalie Peake AU - Emma Beecham AU - Linda J M Oostendorp AU - Briony F Hudson AU - Patrick Stone AU - Louise Jones AU - Monica Lakhanpaul AU - Myra Bluebond-Langner Y1 - 2022/11/01 UR - http://spcare.bmj.com/content/12/e5/e715.abstract N2 - Studies indicate research ethics committee (REC) approval and clinician gatekeeping are two key barriers in recruiting children and young people (CYP) with life-limiting conditions (LLCs) and life-threatening illnesses (LTIs) and their families to research.Objectives To explore the reported experiences, difficulties and proposed solutions of chief investigators (CIs) recruiting CYP with LLCs/LTIs and families in the UK.Methods 61 CIs conducting studies with CYP with LLCs/LTIs and their families, identified from the UK National Institute of Health Research portfolio, completed an anonymous, web-based questionnaire, including both closed and open-ended questions. Descriptive statistics and inductive and deductive coding were used to analyse responses.Results UK CIs cited limitations on funding, governance procedures including Research and Development, Site-Specific and REC approval processes, and clinician gatekeeping as challenges to research. CIs offered some solutions to overcome identified barriers such as working with CYP and their families to ensure their needs are adequately considered in study design and communicated to ethics committees; and designing studies with broad inclusion criteria and developing effective relationships with clinicians in order to overcome clinician gatekeeping.Conclusions Many of the challenges and solutions reported by UK CIs have applicability beyond the UK setting. The involvement of clinicians, patients and their families at the inception of and throughout paediatric palliative care research studies is essential. Other important strategies include having clinician research champions and increasing the visibility of research. Further research on the perspectives of all stakeholders, leading to mutually agreed guidance, is required if care and treatment are to improve. ER -